Home > News > American Pharmaceutical Partners Reports Tolerability of High Dose
June 8th, 2004
American Pharmaceutical Partners Reports Tolerability of High Dose
Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. today reported results of a Phase I dose-escalation study of ABRAXANETM (albumin nanoparticle paclitaxel) that indicated this investigational drug is well-tolerated at high doses in a weekly dosing schedule for non-hematologic malignancies such as lung, ovarian and metastatic breast cancer and patients who have had prior chemotherapies.
Low-power tunneling transistor for high-performance devices at low voltage December 12th, 2013
Chicago Awareness Organization First Not-for-Profit to Sponsor Dog Training to Detect Ovarian Cancer Odorants December 12th, 2013
Iranian Scientists Discover New Electrical Device for Rapid Diagnosis of Cancer December 12th, 2013
Arrowhead to Report Fiscal 2013 Fourth Quarter and Year-End Financial Results - Conference Call Scheduled for Wednesday, December 18, 2013 December 12th, 2013